Tenax Therapeutics, Inc.
General ticker "TENX" information:
- Sector: Health Care
- Industry: Biotechnology
- Capitalization: $470.5M (TTM average)
Tenax Therapeutics, Inc. follows the US Stock Market performance with the rate: 39.3%.
Estimated limits based on current volatility of 3.8%: low 13.38$, high 14.45$
Factors to consider:
- Total employees count: 6 (-25.0%) as of 2023
- Top business risk factors: Inability to continue as a going concern, Economic downturns and volatility, Fluctuating operating results, Product development delays, Market acceptance
- Price in estimated range
Stock Forecast*
* forecast is subjective and experimental, should not be used for any investment decisions
Long term estimates were made for the period from 2025-12-31 to 2027-12-31
- 2025-12-31 to 2026-12-31 estimated range: [4.99$, 15.34$]
- 2026-12-31 to 2027-12-31 estimated range: [2.69$, 9.13$]
Financial Metrics affecting the TENX estimates:
- Negative: with PPE of -9.3 at the end of fiscal year the price was high
- Negative: negative Operating income
- Negative: Operating cash flow per share per price, % of -7.38 <= 0.07
- Positive: Investing cash flow per share per price, % of 0 > -0.65
- Positive: Interest expense per share per price, % of 0 <= 0.01
- Positive: Shareholder equity ratio, % of 93.13 > 64.25
- Negative: negative Net income
- Positive: Inventory ratio change, % of 0 <= 0
Short-term TENX quotes
Long-term TENX plot with estimates
Financial data
| YTD | 2023-12-31 | 2024-12-31 | 2025-12-31 |
|---|---|---|---|
| Operating Revenue | $0.00MM | $0.00MM | $0.00MM |
| Operating Expenses | $8.23MM | $19.49MM | $56.38MM |
| Operating Income | $-8.23MM | $-19.49MM | $-56.38MM |
| Non-Operating Income | $0.52MM | $1.89MM | $3.79MM |
| Interest Expense | $0.02MM | $0.02MM | $0.00MM |
| R&D Expense | $3.23MM | $12.71MM | $32.67MM |
| Income(Loss) | $-7.71MM | $-17.60MM | $-52.60MM |
| Profit(Loss)* | $-7.71MM | $-17.60MM | $-52.60MM |
| Stockholders Equity | $8.10MM | $91.99MM | $97.07MM |
| Assets | $11.68MM | $96.69MM | $104.23MM |
| Operating Cash Flow | $-5.90MM | $-14.81MM | $-35.80MM |
| Investing Cash Flow | $0.00MM | $0.00MM | $0.00MM |
| Financing Cash Flow | $13.57MM | $99.87MM | $38.51MM |
| Earnings Per Share** | $-31.09 | $-1.15 | $-1.34 |
* Profit(Loss) attributable to entity.
** EPS are Split Adjusted, recent splits may be reflected with a delay.